etrasimod (APD334) - Arena
Etrasimod: Completion of enrollment of P3 ELEVATE UC 52 trial (NCT03945188) for ulcerative colitis in Q4 2020 (Arena) - Sep 24, 2020 - Jefferies Virtual Next Generation IBD Therapeutics Summit: Top-line data from P3 ELEVATE UC 52 trial for ulcerative colitis in Q4 2021; Top-line data from P3 ELEVATE UC 12 trial (NCT03996369) for ulcerative colitis in Q4 2021 
Enrollment status • P3 data: top line Inflammatory Bowel Disease • Ulcerative Colitis
https://wsw.com/webcast/jeff143/arna/1829414/
 
Sep 24, 2020
 
 
d05978cb-3dce-4272-91f8-ea713c2620a0.jpg